Atorvastatin improves cognitive, emotional and motor impairments induced by intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration in rats, an experimental model of Parkinson's disease

Brain Research

Volumn 1513, Issue , 2013, Pages 103-116

  Castro, Adalberto A ^a   Wiemes, Bárbara P ^a   Matheus, Filipe C ^a   Lapa, Fernanda R ^a   Viola, Giordano G ^a   Santos, Adair R ^a   Tasca, Carla I ^a   Prediger, Rui D ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

Author keywords

Atorvastatin; Cytokines; Depression; Intranasal; Memory dysfunction; MPTP; Nerve growth factor (NGF); Neuroinflammation; Parkinson's disease; Rat

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ATORVASTATIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; NERVE GROWTH FACTOR; TUMOR NECROSIS FACTOR ALPHA; ANTIPARKINSON AGENT; CYTOKINE; HEPTANOIC ACID DERIVATIVE; PYRROLE DERIVATIVE; SUCROSE; SWEETENING AGENT; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COGNITIVE DEFECT; CONCENTRATION (PARAMETERS); CORPUS STRIATUM; DEPRESSION; DOPAMINERGIC NERVE CELL; EMOTIONAL DISORDER; FORCED SWIMMING TEST; HIPPOCAMPUS; MOTOR DYSFUNCTION; NEUROPROTECTION; NONHUMAN; OPEN FIELD TEST; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SHORT TERM MEMORY; SUBSTANTIA NIGRA PARS COMPACTA; TREATMENT DURATION; ANALYSIS OF VARIANCE; ANIMAL; BRAIN; COGNITION DISORDERS; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; FOOD PREFERENCE; INTRANASAL DRUG ADMINISTRATION; MALE; MAZE TEST; METABOLISM; MOOD DISORDERS; MOTOR ACTIVITY; PARKINSONISM; PATHOLOGY; SOCIAL BEHAVIOR; SWIMMING; WISTAR RAT;

ANIMALIA; RATTUS;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ADMINISTRATION, INTRANASAL; ANALYSIS OF VARIANCE; ANIMALS; ANTIPARKINSON AGENTS; BRAIN; COGNITION DISORDERS; CYTOKINES; DISEASE MODELS, ANIMAL; FOOD PREFERENCES; HEPTANOIC ACIDS; MALE; MAZE LEARNING; MOOD DISORDERS; MOTOR ACTIVITY; PARKINSONIAN DISORDERS; PYRROLES; RATS; RATS, WISTAR; SOCIAL BEHAVIOR; SUCROSE; SWEETENING AGENTS; SWIMMING; TYROSINE 3-MONOOXYGENASE;

EID: 84877584183     PISSN: 00068993     EISSN: 18726240     Source Type: Journal    
DOI: 10.1016/j.brainres.2013.03.029     Document Type: Article

References (66)

1. C. Becker, S.S. Jick, and C.R. Meier Use of statins and the risk of Parkinson's disease: a retrospective case-control study in the UK Drug Saf. 31 2008 399 407
2. C. Becker, and C.R. Meier Statins and the risk of Parkinson disease: an update on the controversy Expert Opin. Drug Saf. 8 2009 261 271
3. E. Bezard, S. Dovero, B. Bioulac, and C. Gross Effects of different schedules of MPTP administration on dopaminergic neurodegeneration in mice Exp. Neurol. 148 1997 288 292
4. J.L. Bosboom, D. Stoffers, and E.C. Wolters Cognitive dysfunction and dementia in Parkinson's disease J. Neural Transm. 111 2004 1303 1315
5. M.M. Bradford A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding Anal. Biochem. 72 1976 248 254
6. A.A. Castro, K. Ghisoni, A. Latini, J. Quevedo, C.I. Tasca, and R.D. Prediger Lithium and valproate prevent olfactory discrimination and short-term memory impairments in the intranasal 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) rat model of Parkinson's disease Behav. Brain Res. 229 2012 208 215
7. K.R. Chaudhuri, and P. Odin The challenge of non-motor symptoms in Parkinson's disease Prog. Brain Res. 184 2010 325 341
8. C. Da Cunha, M.E. Angelucci, N.S. Canteras, S. Wonnacott, and R.N. Takahashi The lesion of the rat substantia nigra pars compacta dopaminergic neurons as a model for Parkinson's disease memory disabilities Cell. Mol. Neurobiol. 22 2002 227 237
9. R. Dantzer, R.M. Bluthe, G.F. Koob, and M. Le Moal Modulation of social memory in male rats by neurohypophyseal peptides Psychopharmacology 91 1987 363 368
10. L.M. De Lau, and M.M. Breteler Epidemiology of Parkinson's disease Lancet Neurol. 5 2006 525 535
11. B. Dubois, and B. Pillon Cognitive deficits in Parkinson's disease J. Neurol. 244 1997 2 8
12. S. Duty, and P. Jenner Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease Br. J. Pharmacol. 164 2011 1357 1391
13. A.C. Ferraz, L.L. Xavier, S. Hernandes, M. Sulzbach, G.G. Viola, J.A. Anselmo-Franci, M. Achaval, and C. Da Cunha Failure of estrogen to protect the substantia nigra pars compacta of female rats from lesion induced by 6-hydroxydopamine Brain Res. 986 2003 200 205
14. X. Gao, K.C. Simon, M.A. Schwarzschild, and A. Ascherio Prospective study of statin use and risk of Parkinson disease Arch. Neurol. 69 2012 380 384
15. A. Ghosh, A. Roy, J. Matras, S. Brahmachari, H.E. Gendelman, and K. Pahan Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson's disease J. Neurosci. 29 2009 13543 13556
16. M.C. Hernández-Romero, S. Argüelles, R.F. Villarán, R.M. de Pablos, M.J. Delgado-Cortés, M. Santiago, A.J. Herrera, J. Cano, and A. Machado Simvastatin prevents the inflammatory process and the dopaminergic degeneration induced by the intranigral injection of lipopolysaccharide J. Neurochem. 105 2008 445 459
17. J. Hippisley-Cox, and C. Coupland Unintended effects of statins in men and women in England and Wales: population based cohort study using the Qresearch database Br. Med. J. 340 2010 c2197
18. E. Hirsch, A.M. Graybiel, and Y.A. Agid Melanized dopamine neurons are differentially susceptible to degeneration in Parkinson's disease Nature 334 1988 345 348
19. E.C. Hirsch, and S. Hunot Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol. 8 2009 382 397
20. M.H. Hsieh, S.L. Gu, S.C. Ho, C.R. Pawlak, C.L. Lin, Y.J. Ho, T.J. Lai, and F.Y. Wu Effects of MK-801 on recognition and neurodegeneration in an MPTP-induced Parkinson's rat model Behav. Brain Res. 229 2012 41 47
21. X. Huang, H. Chen, W.C. Miller, R.B. Mailman, J.L. Woodard, P.C. Chen, D. Xiang, R.W. Murrow, Y.Z. Wang, and C. Poole Lower low-density lipoprotein cholesterol levels are associated with Parkinson's disease Mov. Disord. 22 2007 377 381
22. H. Jick, G.L. Zornberg, S.S. Jick, S. Seshadri, and D.A. Drachman Statins and the risk of dementia Lancet 356 2000 1627 1631
23. A. Kreisler, P. Gelé, J.F. Wiart, M. Lhermitte, A. Destée, and R. Bordet Lipid-lowering drugs in the MPTP mouse model of Parkinson's disease: fenofibrate has a neuroprotective effect, whereas bezafibrate and HMG-CoA reductase inhibitors do not Brain Res. 1135 2007 77 84
24. A. Kumar, N. Sharma, A. Gupta, H. Kalonia, and J. Mishra Neuroprotective potential of atorvastatin and simvastatin (HMG-CoA reductase inhibitors) against 6-hydroxydopamine (6-OHDA) induced Parkinson-like symptoms Brain Res. 1471 2012 13 22
25. G.T. Liberatore, V. Jackson-Lewis, S. Vukosavic, A.S. Mandir, M. Vila, W.G. McAuliffe, V.L. Dawson, T.M. Dawson, and S. Przedborski Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease Nat. Med. 5 1999 1403 1409
26. L. Lorigados Pedre, N. Pavón Fuentes, L. Alvarez González, A. McRae, T. Serrano Sánchez, Blanco, L. Lescano, and R. Macías González Nerve growth factor levels in Parkinson disease and experimental parkinsonian rats Brain Res. 952 2002 122 127
27. Ludka, F.K., Zomkowski, A.D., Cunha, M.P., Dal-Cim, T., Zeni, A.L., Rodrigues, A.L., Tasca, C,I., 2012. Acute atorvastatin treatment exerts antidepressant-like effect in mice via the l-arginine-nitric oxide-cyclic guanosine monophosphate pathway and increases BDNF levels. Eur. Neuropsychopharmacol. (http://dx.doi.org/10.1016/j.euroneuro.2012.05.005)
28. F.C. Matheus, As. Aguiar Jr., A.A. Castro, J.G. Villarinho, J. Ferreira, C.P. Figueiredo, R. Walz, A.R. Santos, C.I. Tasca, and R.D. Prediger Neuroprotective effects of agmatine in mice infused with a single intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) Behav. Brain Res. 235 2012 263 272
29. P.L. McGeer, S. Itagaki, B.E. Boyes, and E.G. McGeer Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains Neurology 38 1988 1285 1291
30. E. Miyoshi, S. Wietzikoski, M. Camplessei, R. Silveira, R.N. Takahashi, and C. Da Cunha Impaired learning in a spatial working memory version and in a cued version of the water maze in rats with MPTP-induced mesencephalic dopaminergic lesions Brain Res. Bull. 58 2002 41 47
31. M. Mogi, M. Harada, T. Kondo, P. Riederer, H. Inagaki, M. Minami, and T. Nagatsu Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients Neurosci. Lett. 180 1994 147 150
32. E.L. Moreira, D. Rial, A.S. Aguiar Jr, C.P. Figueiredo, J.M. Siqueira, S. DalBó, H. Horst, J. de Oliveira, G. Mancini, T.S. dos Santos, J.G. Villarinho, F.V. Pinheiro, J. Marino-Neto, J. Ferreira, A.F. De Bem, A. Latini, M.G. Pizzolatti, R.M. Ribeiro-do-Valle, and R.D. Prediger Proanthocyanidin-rich fraction from Croton celtidifolius Baill confers neuroprotection in the intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine rat model of Parkinson's disease J. Neural Transm. 117 2010 1337 1351
33. R.G.M. Morris, P. Garrud, J.N. Rawlins, and J. O'keefe Place navigation impaired in rats with hippocampal lesions Nature 297 1982 681 683
34. T. Nagatsu, M. Mogi, H. Ichinose, and A. Togari Cytokines in Parkinson's disease J. Neural Transm. Suppl. 58 2000 143 151
35. T.C. Piermartiri, C.P. Figueiredo, D. Rial, F.S. Duarte, S.C. Bezerra, G. Mancini, A.F. de Bem, R.D. Prediger, and C.I. Tasca Atorvastatin prevents hippocampal cell death, neuroinflammation and oxidative stress following amyloid-β(1-40) administration in mice: evidence for dissociation between cognitive deficits and neuronal damage Exp. Neurol. 226 2010 274 284
36. T.C. Piermartiri, S. Vandresen-Filho, B. de Araújo Herculano, W.C. Martins, D. Dal'agnolo, E. Stroeh, C.L. Carqueja, C.R. Boeck, and C.I. Tasca Atorvastatin prevents hippocampal cell death due to quinolinic acid-induced seizures in mice by increasing Akt phosphorylation and glutamate uptake Neurotox. Res. 16 2009 106 115
37. R.D. Porsolt, M. Le Pichon, and M. Jalfre Depression: a new animal model sensitive to antidepressant treatments Nature 266 1977 730 732
38. R.D. Prediger, A.S. Aguiar Jr, E.L. Moreira, F.C. Matheus, A.A. Castro, R. Walz, A.F. De Bem, A. Latini, C.I. Tasca, M. Farina, and R. Raisman-Vozari The intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a new rodent model to test palliative and neuroprotective agents for Parkinson's disease Curr. Pharm. Des. 17 2011 489 507
39. R.D. Prediger, A.S. Aguiar Jr, A.E. Rojas-Mayorquin, C.P. Figueiredo, F.C. Matheus, L. Ginestet, C. Chevarin, E.D. Bel, R. Mongeau, M. Hamon, L. Lanfumey, and R. Raisman-Vozari Single intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice models early preclinical phase of Parkinson's disease Neurotox. Res. 2 2010 114 129
40. R.D. Prediger, L.C. Batista, R. Medeiros, P. Pandolfo, J.C. Florio, and R.N. Takahashi The risk is in the air: Intranasal administration of MPTP to rats reproducing clinical features of Parkinson's disease Exp. Neurol. 202 2006 391 403
41. R.D. Prediger, L.C. Batista, E. Miyoshi, and R.N. Takahashi Facilitation of short-term social memory by ethanol in rats is mediated by dopaminergic receptors Behav. Brain Res. 153 2004 149 157
42. R.D. Prediger, C. Da Cunha, and R.N. Takahashi Antagonistic interaction between adenosine A2A and dopamine D2 receptors modulates the social recognition memory in reserpine-treated rats Behav. Pharmacol. 16 2005 209 218
43. R.D. Prediger, D. Rial, R. Medeiros, C.P. Figueiredo, R.L. Doty, and R.N. Takahashi Risk is in the air: an intranasal MPTP (1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine) rat model of Parkinson's disease Ann. N.Y. Acad. Sci. 1170 2009 629 636
44. S. Przedborski, V. Jackson-Lewis, A.B. Naini, M. Jakowec, G. Petzinger, R. Miller, and M. Akram The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP): a technical review of its utility and safety J. Neurochem. 76 2001 1265 1274
45. B. Ritz, A.D. Manthripragada, L. Qian, E. Schernhammer, L. Wermuth, J. Olsen, and S. Friis Statin use and Parkinson's disease in Denmark Mov. Disord. 25 2010 1210 1216
46. M. Salinas, R. Diaz, N.G. Abraham, C.M. Ruiz de Galarreta, and A. Cuadrado Nerve growth factor protects against 6-hydroxydopamine-induced oxidative stress by increasing expression of heme oxygenase-1 in a phosphatidylinositol 3-kinase-dependent manner J. Biol. Chem. 278 2003 13898 13904
47. R.M. Santiago, J. Barbieiro, M.M. Lima, P.A. Dombrowski, R. Andreatini, and M.A. Vital Depressive-like behaviors alterations induced by intranigral MPTP, 6-OHDA, LPS and rotenone models of Parkinson's disease are predominantly associated with serotonin and dopamine Prog. Neuropsychopharmacol. Biol. Psychiatry 34 2010 1104 1114
48. T.F. Sawyer, A.K. Hengehold, and W.A. Perez Chemosensory and hormonal mediation of social memory in male rats Behav. Neurosci. 98, 1984 908-1113
49. M. Sedelis, K. Hofele, G.W. Auburger, S. Morgan, J.P. Huston, and R.K. Schwarting MPTP susceptibility in the mouse: behavioral, neurochemical, and histological analysis of gender and strain differences Behav. Genet. 30 2000 171 182
50. M.L. Selley Simvastatin prevents 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-induced striatal dopamine depletion and protein tyrosine nitration in mice Brain Res. 1037 2005 1 6
51. K. Shimoke, and H. Chiba Nerve growth factor prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced cell death via the Akt pathway by suppressing caspase-3-like activity using PC12 cells: relevance to therapeutical application for Parkinson's disease J. Neurosci. Res. 63 2001 402 409
52. D.A. Slattery, A. Markou, and J.F. Cryan Evaluation of reward processes in an animal model of depression Psychopharmacology 190 2007 555 568
53. K. Sriram, J.M. Matheson, S.A. Benkovic, D.B. Miller, M.I. Luster, and J.P. O'Callaghan Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson's disease FASEB J. 16 2002 1474 1476
54. M.T. Tadaiesky, P.A. Dombrowski, C.P. Figueiredo, E. Cargnin-Ferreira, C. Da Cunha, and R.N. Takahashi Emotional, cognitive and neurochemical alterations in a premotor stage model of Parkinson's disease Neuroscience 156 2008 830 840
55. T.N. Taylor, J.G. Greene, and G.W. Miller Behavioral phenotyping of mouse models of Parkinson's disease Behav. Brain Res. 211 2010 1 10
56. E. Tolosa, Y. Compta, and C. Gaig The premotor phase of Parkinson's disease Parkinsonism. Relat. Disord. 13 2007 2 7
57. C. Vieira, T.C. De Lima, A. de P. Carobrez, and C. Lino-de-Oliveira Frequency of climbing behavior as a predictor of altered motor activity in rat forced swimming test Neurosci. Lett. 445 2008 170 173
58. A.D. Wahner, J.M. Bronstein, Y.M. Bordelon, and B. Ritz Statin use and the risk of Parkinson disease Neurology 70 2008 1418 1422
59. A.L. Wang, Y.M. Liou, C.R. Pawlak, and Y.J. Ho Involvement of NMDA receptors in both MPTP-induced neuroinflammation and deficits in episodic-like memory in Wistar rats Behav. Brain Res. 208 2010 38 46
60. Q. Wang, J. Yan, X. Chen, J. Li, Y. Yang, J. Weng, C. Deng, and M.A. Yenari Statins: multiple neuroprotective mechanisms in neurodegenerative diseases Exp. Neurol. 230 2011 27 34
61. W.F. Wang, S.L. Wu, Y.M. Liou, A,L. Wang, C.R. Pawlak, and Y.J. Ho MPTP lesion causes neuroinflammation and deficits in object recognition in Wistar rats Behav. Neurosci. 123 2009 1261 1270
62. B. Wolozin, S.W. Wang, N.C. Li, A. Lee, T.A. Lee, and L.E. Kazis Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease B.M.C. Med. 5 2007 20
63. W.G. Wood, G.P. Eckert, U. Igbavboa, and W.E. Müller Statins and neuroprotection: a prescription to move the field forward Ann. N. Y. Acad. Sci. 1199 2010 69 76
64. J. Yan, Y. Xu, C. Zhu, L. Zhang, A. Wu, Y. Yang, Z. Xiong, C. Deng, X.F. Huang, M.A. Yenari, Y.G. Yang, W. Ying, and Q. Wang Simvastatin prevents dopaminergic neurodegeneration in experimental parkinsonian models: the association with anti-inflammatory responses PLoS One 6 2011 e20945
65. Y.K. Young-Xu, A. Chan, J.K. Liao, S. Ravid, and C.M. Blatt Long-term statin use and psychological well-being J. Am. Coll. Cardiol. 42 2003 690 697
66. D.J. Zgaljardic, J.C. Borod, N.S. Foldi, and P. Mattis A review of the cognitive and behavioral sequelae of Parkinson's disease: relationship to frontostriatal circuitry Cogn. Behav. Neurol. 16 2003 193 210